Neumora Therapeutics Past Earnings Performance
Past criteria checks 0/6
Neumora Therapeutics's earnings have been declining at an average annual rate of -19.6%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually.
Key information
-19.6%
Earnings growth rate
44.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -91.6% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Revenue & Expenses Breakdown
How Neumora Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -294 | 57 | 194 |
| 30 Jun 24 | 0 | -274 | 56 | 175 |
| 31 Mar 24 | 0 | -254 | 50 | 159 |
| 31 Dec 23 | 0 | -236 | 45 | 143 |
| 30 Sep 23 | 0 | -155 | 41 | 127 |
| 30 Jun 23 | 0 | -132 | 34 | 108 |
| 31 Mar 23 | 0 | -123 | 33 | 99 |
| 31 Dec 22 | 0 | -131 | 31 | 92 |
| 30 Sep 22 | 0 | -130 | 32 | 87 |
| 30 Jun 22 | 0 | -278 | 30 | 79 |
| 31 Mar 22 | 0 | -265 | 29 | 66 |
| 31 Dec 21 | 0 | -237 | 25 | 56 |
| 30 Sep 21 | 0 | -230 | 21 | 47 |
| 31 Dec 20 | 0 | -99 | 8 | 17 |
Quality Earnings: NMRA is currently unprofitable.
Growing Profit Margin: NMRA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NMRA is unprofitable, and losses have increased over the past 5 years at a rate of 19.6% per year.
Accelerating Growth: Unable to compare NMRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NMRA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: NMRA has a negative Return on Equity (-91.57%), as it is currently unprofitable.